Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma Authors: F A Sharpley, F Djebbari, S Fourali, J Kothari, J A Lynes, S McLain-Smith, K Ramasamy Published: Leukemia and Lymphoma, 2019 View publication Thought Leadership Innovation is only the first step Thought Leadership Recognizing the wider impact of a dementia diagnosis Thought Leadership What we don’t measure still matters
